logo

Tcr2 Therapeutics (TCRR)



Trade TCRR now with
  Date
  Headline
4/2/2019 8:07:43 AM Wedbush Is Cutting TCR2 Therapeutics (TCRR) FY20 Estimate To -2.85 From -2.42
4/2/2019 8:07:28 AM Wedbush Is Lowering TCR2 Therapeutics (TCRR) Q4 20 Estimate To -0.68 From -0.58
4/2/2019 8:07:13 AM Wedbush Is Cutting TCR2 Therapeutics (TCRR) Q3 20 Estimate To -0.76 From -0.64
4/2/2019 8:07:01 AM Wedbush Is Cutting TCR2 Therapeutics (TCRR) Q2 20 Estimate To -0.72 From -0.61
4/2/2019 8:06:48 AM Wedbush Is Cutting TCR2 Therapeutics (TCRR) Q1 20 Estimate To -0.69 From -0.58
4/2/2019 8:06:33 AM Wedbush Is Lowering TCR2 Therapeutics (TCRR) FY19 Estimate To -2.04 From -1.72
4/2/2019 8:06:17 AM Wedbush Is Cutting TCR2 Therapeutics (TCRR) Q4 19 Estimate To -0.65 From -0.56
4/2/2019 8:06:03 AM Wedbush Is Lowering TCR2 Therapeutics (TCRR) Q3 19 Estimate To -0.53 From -0.45
4/2/2019 8:05:50 AM Wedbush Is Lowering TCR2 Therapeutics (TCRR) Q2 19 Estimate To -0.45 From -0.38
4/2/2019 8:05:34 AM Wedbush Is Lowering TCR2 Therapeutics (TCRR) Q1 19 Estimate To -0.39 From -0.33
4/1/2019 7:22:02 AM TCR2 Therapeutics 2018 Net Loss $24.3 Mln
3/26/2019 7:06:16 AM TCR2 Announces Collaboration With Cell And Gene Therapy Catapult For Manufacturing Of Novel T Cell Therapies
3/11/2019 6:46:10 AM Wedbush Starts TCR2 Therapeutics (TCRR) At Outperform With $28 Price Target